Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 109
Filter
1.
Millat-Martinez, Pere, Gharbharan, Arvind, Alemany, Andrea, Casper, Rokx, Geurtsvankessel, Corine, Papageourgiou, Grigorios, Nan, van Geloven, Jordans, Carlijn, Groeneveld, Geert, Swaneveld, Francis, van der Schoot, Ellen, Corbacho-Monné, Marc, Ouchi, Dan, Piccolo Ferreira, Francini, Malchair, Pierre, Videla, Sebastian, García García, Vanesa, Ruiz-Comellas, Anna, Ramírez-Morros, Anna, Rodriguez Codina, Joana, Amado, Simon Rosa, Joan-Ramon, Grifols, Blanco, Julian, Blanco, Ignacio, Ara, Jordi, Bassat, Quique, Bonaventura, Clotet, Baro, Bàrbara, Troxel, Andrea, Zwaginga, Jaap Jan, Mitjà, Oriol, Rijnders Bart, J. A.; Rijnders, Bart, Katsikis, Peter, Müller, Yvonne, Koopmans, Marion, Bogers, Susanne, Miedema, Jelle, Russcher, Henk, Scherpenisse, Cees, van Engen, Rene, Karisli, Ayten, Götz, Hannelore, Struik, Jelle, Rokx-Niemantsverdriet, Lotte, Jan Zwaginga, Jaap, Zwaginga, Lisa, Oud, Josine, Meier, Romy, van Zwet, Erik, Mooijaart, Simon, Albersen, Arjan, Vrielink, Hans, van de Watering, Leo, Hogema, Boris, van Wijngaarden, Peter, van Etten, Ronald, van Gammeren, Adriaan, Maas, Nanda, van Ginneken, Betty, den Hollander, Jan, Verstijnen, Jose, van den Berg – Rahman, Juliette, Karim, Faiz, Siepke, Hiddema, van Elst, Kim, van Leeuwen-Segarceanu, Elena, Reitsma, Annette, Molenkamp, Karin, Soetekouw, Robert, Band, Caterina, de Droog, José, Lammers, Jolanda, Buitenhuis, Lonneke, Postma, Douwe, Koster, David, Lukens, Michaèl, Scholtens, Thea, van den Boomgaard, Maartje, Vonk, Machiel, Kampschreur, Linda, van Vonderen, Marit, Vrolijk, Loes, Reusken, Chantal, Reimerink, Johan, Harvala, Heli, Costes, Gèlia, Capdevila-Jáuregui, Mar, Torrano-Soler, Pamela, San José, Alba, Jiménez, Zahida, Ramírez-Viaplana, Ferran, Ferrer, Susana, Gallardo, Mireia, Ubals, Maria, González-Beiras, Camila, Vall-Mayans, Martí, Rodriguez-Arias, Miquel Angel, Suñer, Clara, Puig, Jordi, Nieto, Aroa, Galvan-Femenia, Ivan, Comas-Leon, Xavier, Millat-Martínez, Pere, Bonet Papell, Glòria, Delgado Capel, Maria, Díez Sánchez, Beatriz, Pons Barber, Maria, Gonzalez Ruiz, Cristian, Navarrete Gonzalez, Laura, González García, David, Vivero Larraza, Ainhoa, Carceles Peiró, Victor, Roquer López, Clàudia, Ferrer, Magí, Gudiol, Carlota, Otero, Aurema, Ruibal Suarez Jose, Carlos, Pellejero Alvaro, Zarauza, Llopis Roca, Ferran, Rodriguez Cortez, Orlando, Casares Gonzalez, Pablo, Arcos Vila, Gemma, Flores Aguilera, Begoña, Rodríguez-Sevilla, Graciela, Dastis Arias, Macarena, Roca Font, Judit, Carrasco Matos Katherine, M.; Glòria, Saüch Valmaña, Vidal Obradors, Carla, Rodríguez Codina, Joana, Tarres García, Silvia, Curriu, Sabatès Margarida, Nieto Rodríguez, Raquel, Joan-Ramon, Grífols, Millan, Anna, Contreras, Enric, Ancochea, Àgueda, Línio, Rosa, Fornos, Miriam, Casamitjana, Natàlia, Alonso, Eva, Martinez, Núria, Maglio, Laura Analía, Comellas Fernandez, Laura, Garcia, Nadia, Hernández, Luis, González, María Isabel, Bravo, Anna, García, Yolanda, Prat, Núria, Verdaguer, Joaquim, Vértiz Guidotti, Thatiana, Benavent, Sergio, Bianco, Andrea Sofia, Briones Zambrano Ney, Nicanor, Viozquez Meya, Maria, Forcada, Anna, Vidal-Alaball, Josep, Giménez, Montserrat, París, Alexa, Fernández, Rivas Gema, Casañ Lopez, Cristina, Hernández, Águeda, Bordoy, Antoni E.; González Soler, Victoria, Edwars, Pradenas, Marfil, Silvia, Trinité, Benjamin, Bonet, Mireia, Cantoni, Jordi, Marks, Michael.
Nature Communications ; 13(1), 2022.
Article in English | ProQuest Central | ID: covidwho-1839524

ABSTRACT

Data on convalescent plasma (CP) treatment in COVID-19 outpatients are scarce. We aimed to assess whether CP administered during the first week of symptoms reduced the disease progression or risk of hospitalization of outpatients. Two multicenter, double-blind randomized trials (NCT04621123, NCT04589949) were merged with data pooling starting when <20% of recruitment target was achieved. A Bayesian-adaptive individual patient data meta-analysis was implemented. Outpatients aged ≥50 years and symptomatic for ≤7days were included. The intervention consisted of 200–300mL of CP with a predefined minimum level of antibodies. Primary endpoints were a 5-point disease severity scale and a composite of hospitalization or death by 28 days. Amongst the 797 patients included, 390 received CP and 392 placebo;they had a median age of 58 years, 1 comorbidity, 5 days symptoms and 93% had negative IgG antibody-test. Seventy-four patients were hospitalized, 6 required mechanical ventilation and 3 died. The odds ratio (OR) of CP for improved disease severity scale was 0.936 (credible interval (CI) 0.667–1.311);OR for hospitalization or death was 0.919 (CI 0.592–1.416). CP effect on hospital admission or death was largest in patients with ≤5 days of symptoms (OR 0.658, 95%CI 0.394–1.085). CP did not decrease the time to full symptom resolution.Trial registration: Clinicaltrials.gov NCT04621123 and NCT04589949. Registration: NCT04621123 and NCT04589949 on https://www.clinicaltrials.govClinical studies have suggested that the therapeutic potential of polyclonal convalescent plasma is highest in the first days of symptoms. Here, the authors present results from a pooled analysis of two clinical trials in COVID-19 outpatients that did not provide conclusive evidence in favor of convalescent plasma.

3.
Medicina Clínica (English Edition) ; 2022.
Article in English | ScienceDirect | ID: covidwho-1814947

ABSTRACT

Catatonia is an undertreated and underdiagnosed neuropsychiatric syndrome whose prognosis is benign if treated early, thus avoiding possible complications and compromising the health of patients. The latest epidemiological studies indicate a prevalence of catatonia of 9.2%, being frequent in medical pathologies (especially neurological ones), as well as in psychiatric pathologies. The use of validated scales is recommended for its diagnosis, to be able to measure the severity and response to treatment. Once catatonia has been identified, it is necessary to perform a protocolized diagnostic study of the underlying aetiology («Catatonia Workup»). Treatment of choice is benzodiazepines and electroconvulsive therapy. In recent years, new therapeutic alternatives such as non-invasive transcranial magnetic stimulation have emerged. In this review we propose several initiatives to promote the dissemination and knowledge of catatonia in the clinical setting. Resumen La catatonia es un síndrome neuropsiquiátrico infratratado e infradiagnósticado cuyo pronóstico es benigno si se trata de forma precoz, evitando así posibles complicaciones y el compromiso de la salud de los pacientes. Los últimos estudios epidemiológicos señalan una prevalencia de catatonia del 9,2%, siendo frecuente tanto en las enfermedades médicas (especialmente en las neurológicas), como en las psiquiátricas. Es recomendable el uso de escalas validadas para su diagnóstico y poder medir la gravedad y la respuesta al tratamiento. Una vez identificada la catatonia, es necesario realizar un estudio diagnóstico protocolizado de la etiología subyacente («Catatonia Workup»). El tratamiento de elección son las benzodiacepinas y la terapia electroconvulsiva. En los últimos años, han surgido nuevas alternativas terapéuticas no invasivas, tales como la estimulación magnética transcraneal. En esta revisión, proponemos varias iniciativas para fomentar la difusión y el conocimiento de la catatonia en el ámbito clínico.

4.
EuropePMC; 2022.
Preprint in English | EuropePMC | ID: ppcovidwho-334251

ABSTRACT

Background: Contemporary societies lack direct evidence that diversity of neuro-origin psychological traits – neurodiversity – benefits the human species. Psychological diversities including those with heightened traits of obsessive-compulsiveness (OC) may play a critical preventative role amidst a pandemic because of their natural dispositions for immunizing cognitions and behaviors based on obsessive pathogen concerns. We aim to test this notion in the context of the coronavirus disease 2019 (COVID-19) pandemic. Methods: : We will conduct an online survey examining the hypotheses that individuals with higher psychological traits of OC are less likely to get infected while they show enhanced self-diagnosis of infection. Conclusions: : Such results would suggest that those generally perceived as “psychological minorities” due to increased pathogen concerns may serve preventive roles against pandemics at both individual and collective levels.

5.
Observatorio (OBS*) ; 16(1):160, 2022.
Article in Spanish | ProQuest Central | ID: covidwho-1771914

ABSTRACT

Introducción: La epidemia de COVID-19 puso sobre la mesa la infodemia como un factor agravante de la emergencia sanitaria, situación que realzó el papel del periodismo de verificación de datos en situaciones de crisis. Este artículo analiza la actividad en Facebook de la agrupación internacional de fact-checking LatamChequea Coronavirus durante los dos primeros meses tras la declaración de pandemia por COVID-19 realizada por la OMS (11 de marzo 2020 – 11 de mayo 2020). Metodología: Se analizaron los contenidos, metadatos y reacciones generadas en un total de 5736 posts publicados por 31 fact-checkers distintos. Resultados: Entre las publicaciones más compartidas, las relacionadas con la COVID-19 generaron más reacciones y comentarios que las referidas a otras temáticas;el volumen de compartidos es elevado en relación con otras interacciones generalmente más frecuentes y las publicaciones que incluyen enlaces lograron más interacciones de todo tipo que las basadas en vídeos o imágenes. Se observan correlaciones positivas entre el número de likes y el número de veces que un post ha sido compartido, y entre la reacción de enfado y el número de comentarios. Discusión y conclusiones: La relevancia de los compartidos en el conjunto de interacciones indicaría un interés elevado de los usuarios por compartir los desmentidos sobre noticias falsas, algo que se distancia de investigaciones previas referenciadas. Los resultados apuntan también a la influencia de la reacción emocional expresada en la interacción con el contenido en forma de compartido o comentario.Alternate :The COVID-19 pandemic revealed infodemics as an aggravating factor in health emergencies, a situation that enhanced the role of data verification journalism in crisis situations. This article aims to know the dynamics of publication and interaction on Facebook of the international fact-checking group LatamChequea Coronavirus during the first two months after the declaration of the COVID-19 pandemic by the WHO (March 11, 2020 - May 11, 2020). Methodology: The contents, metadata and reactions generated in a total of 5736 posts published by 31 different fact-checkers were collected with Crowdtangle and analyzed. Results: Among the most shared publications, those related to the COVID19 generated more reactions and comments than those referring to other topics;the volume of shares is high in relation to other generally more frequent interactions and publications that include links achieved more interactions of all kinds than those based on videos or images. There are positive correlations between the number of likes and the number of shares, and between the angry reaction and the number of comments. Discussion and conclusions: The relevance of sharing in the set of interactions would indicate a high interest of the users to share the denials about fake news, something that distances from previous referenced investigations. The results also point to the influence of the emotional reaction expressed in the interaction with the content in the form of sharing or commenting.

6.
J Clin Med ; 11(7)2022 Mar 25.
Article in English | MEDLINE | ID: covidwho-1771213

ABSTRACT

The SARS-CoV-2 pandemic might have increased the risks of healthcare-associated infections (HAIs); however, several studies of HAI such as urinary tract infections (UTIs) and catheter-associated urinary tract infections (CAUTIs) have shown contradictory results. The aim of this study is to assess the clinical features of UTIs and bacterial isolates from urine samples of hospitalized COVID-19 patients. We conducted a retrospective observational study including 87 COVID-19 patients with UTIs admitted to our centre. Bacterial UTIs presented were 87: 9 (10.3%) community-acquired UTIs (coinfection group) and 78 (89.6%) hospital-acquired UTIs (superinfection group). In the coinfection group, the most frequent type was non-CAUTI with 5 (55.5%) patients; however, the most frequent UTI in the superinfection group was CAUTI, with 53 (67.9%) patients. The median number of days of hospitalization in coinfected patients was lower than superinfection patients: 13 (IQR 11, 23) vs. 34 days (IQR 23, 47) p < 0.006. All UTI patients admitted to ICU, 38 (43.7%), belonged to the superinfection group. The mortality rate was 26.4% (23/87), 22/23 in the superinfection group. The most common microorganisms were E. coli 27 (28.4%), E. faecalis 25 (26.3%) and E. faecium 20 (21.1%). There was an increased incidence of E. faecalis and E. faecium in UTIs as well as hospital-acquired UTIs. This can be related to urethral catheterization during hospitalization, UCI admissions and the number of days of hospitalization.

7.
Int J Environ Res Public Health ; 19(6)2022 Mar 10.
Article in English | MEDLINE | ID: covidwho-1765707

ABSTRACT

Politics is ubiquitous in public health, but vaccines had never been weaponized to instill distrust to gain political advantage. In pandemic and post-pandemic scenarios, populist political parties could use vaccine-related issues to generate distrust in evidence-based knowledge. Therefore, some questions arise. What impact could populist political parties impinge on vaccination uptake rates through sowing political discontent? What could the medical institutions do to avoid the adverse effects that these political strategies could infringe? For answering these research questions, we first hypothesized that vaccine uptake was negatively associated with distrust in the institutions. Furthermore, we analyzed whether populism mediates this relationship. In doing so, we hypothesized a positive association between distrust and populism, because populists, mainly fueled by politically discontent citizens, offer hope of a better future, blaming their misfortune on the actions of the elite. Additionally, we hypothesized that those citizens with a higher level of political dissatisfaction, following the claims of the populist political parties, will have lower vaccine uptake results, because they will be discouraged from making the efforts to counter the pandemic. Based on a survey carried out by the European Commission that covered 27 E.U. + U.K. countries (totaling 27,524 respondents), this paper proves that an individual's political discontent fully mediates the relationship between distrust in institutions and vaccine uptake. Targeting the vaccine-hesitant population is quite convenient for populists because they only need to convince a minority of citizens not to be vaccinated to achieve their destabilizing goals. New outbreaks will appear if the minimum herd immunity coverage is not reached, reinforcing a vicious circle of distrust in elites, in consequence. For tackling this matter, recommendations are given to institutional managers from a social marketing standpoint.

8.
Hall, Andrew J.; Clement, Nicholas D.; Ojeda-Thies, Cristina, MacLullich, Alasdair M. J.; Toro, Giuseppe, Johansen, Antony, White, Tim O.; Duckworth, Andrew D.; Abdul-Jabar, Hani, Abu-Rajab, Rashid, Abugarja, Ahmed, Adam, Karen, Aguado Hernández, Héctor J.; Améstica Lazcano, Gedeón, Anderson, Sarah, Ansar, Mahmood, Antrobus, Jonathan, Aragón Achig, Esteban Javier, Archunan, Maheswaran, Arrieta Salinas, Mirentxu, Ashford-Wilson, Sarah, Assens Gibert, Cristina, Athanasopoulou, Katerina, Awadelkarim, Mohamed, Baird, Stuart, Bajada, Stefan, Balakrishnan, Shobana, Balasubramanian, Sathishkumar, Ballantyne, James A.; Bárcena Goitiandia, Leopoldo, Barkham, Benjamin, Barmpagianni, Christina, Barres-Carsi, Mariano, Barrett, Sarah, Baskaran, Dinnish, Bell, Jean, Bell, Katrina, Bell, Stuart, Bellelli, Giuseppe, Benchimol, Javier Alberto, Boietti, Bruno Rafael, Boswell, Sally, Braile, Adriano, Brennan, Caitlin, Brent, Louise, Brooke, Ben, Bruno, Gaetano, Burahee, Abdus, Burns, Shirley, Calabrò, Giampiero, Campbell, Lucy, Carabelli, Guido Sebastian, Carnegie, Carol, Carretero Cristobal, Guillermo, Caruana, Ethan, Cassinello Ogea, M. Concepción, Castellanos Robles, Juan, Castillon, Pablo, Chakrabarti, Anil, Cecere, Antonio Benedetto, Chen, Ping, Clarke, Jon V.; Collins, Grace, Corrales Cardenal, Jorge E.; Corsi, Maurizio, Cózar Adelantado, Gara María, Craxford, Simon, Crooks, Melissa, Cuarental-García, Javier, Cuthbert, Rory, Dall, Graham, Daskalakis, Ioannis, De Cicco, Annalisa, Diana, de la Fuente de Dios, Demaria, Pablo, Dereix, John, Díaz Jiménez, Julian, Dinamarca Montecinos, José Luis, Do Le, Ha Phuong, Donoso Coppa, Juan Pablo, Drosos, Georgios, Duffy, Andrew, East, Jamie, Eastwood, Deborah, Elbahari, Hassan, Elias de Molins Peña, Carmen, Elmamoun, Mamoun, Emmerson, Ben, Escobar Sánchez, Daniel, Faimali, Martina, Farré-Mercadé, Maria Victòria, Farrow, Luke, Fayez, Almari, Fell, Adam, Fenner, Christopher, Ferguson, David, Finlayson, Louise, Flores Gómez, Aldo, Freeman, Nicholas, French, Jonathan, Gabardo Calvo, Santiago, Gagliardo, Nicola, Garcia Albiñana, Joan, García Cruz, Guillermo, García de Cortázar Antolín, Unai, García Virto, Virginia, Gealy, Sophie, Gil Caballero, Sandra Marcela, Gill, Moneet, González González, María Soledad, Gopireddy, Rajesh, Guntley, Diane, Gurung, Binay, Guzmán Rosales, Guadalupe, Haddad, Nedaa, Hafeez, Mahum, Haller, Petra, Halligan, Emer, Hardie, John, Hawker, Imogen, Helal, Amr, Herrera Cruz, Mariana, Herreros Ruiz-Valdepeñas, Ruben, Horton, James, Howells, Sean, Howieson, Alan, Hughes, Luke, Hünicken Torrez, Flavia Lorena, Hurtado Ortega, Ana, Huxley, Peter, Hamid, Hytham K. S.; Ilahi, Nida, Iliadis, Alexis, Inman, Dominic, Jadhao, Piyush, Jandoo, Rajan, Jawad, Lucy, Jayatilaka, Malwattage Lara Tania, Jenkins, Paul J.; Jeyapalan, Rathan, Johnson, David, Johnston, Andrew, Joseph, Sarah, Kapoor, Siddhant, Karagiannidis, Georgios, Karanam, Krishna Saga, Kattakayam, Freddy, Konarski, Alastair, Kontakis, Georgios, Labrador Hernández, Gregorio, Lancaster, Victoria, Landi, Giovanni, Le, Brian, Liew, Ignatius, Logishetty, Kartik, Lopez Marquez, Andrew Carlomaria Daniel, Lopez, Judit, Lum, Joann, Macpherson, Gavin J.; Madan, Suvira, Mahroof, Sabreena, Malik-Tabassum, Khalid, Mallina, Ravi, Maqsood, Afnan, Marson, Ben, Martin Legorburo, M. José, Martin-Perez, Encarna, Martínez Jiménez, Tania, Martinez Martin, Javier, Mayne, Alistair, Mayor, Amy, McAlinden, Gavan, McLean, Lucille, McDonald, Lorna, McIntyre, Joshua, McKay, Pamela, McKean, Greg, McShane, Heather, Medici, Antonio, Meeke, Chelsea, Meldrum, Evonne, Mendez, Mijail, Mercer, Scott, Merino Perez, Josu, Mesa-Lampré, María-Pilar, Mighton, Shuna, Milne, Kirsty, Mohamed Yaseen, Muhammed, Moppett, Iain, Mora, Jesus, Morales-Zumel, Sira, Moreno Fenoll, Irene Blanca, Mousa, Adham, Murray, Alastair W.; Murray, Elspeth V.; Nair, Radhika, Neary, Fiona, Negri, Giacomo, Negus, Oliver, Newham-Harvey, Fiona, Ng, Nigel, Nightingale, Jess, Noor Mohamed Anver, Sumiya, Nunag, Perrico, O'Hare, Matthew, Ollivere, Ben, Ortés Gómez, Raquel, Owens, AnneMarie, Page, Siobhan, Palloni, Valentina, Panagiotopoulos, Andreas, Panagiotopoulos, Elias, Panesar, Paul, Papadopoulos, Antonios, Spyridon, Papagiannis, Pareja Sierra, Teresa, Park, Chang, Parwaiz, Hammad, Paterson-Byrne, Paul, Patton, Sam, Pearce, Jack, Porter, Marina, Pellegrino, Achille, Pèrez Cuellar, Arturo, Pezzella, Raffaele, Phadnis, Ashish, Pinder, Charlotte, Piper, Danielle, Powell-Bowns, Matilda, Prieto Martín, Rocío, Probert, Annabel, Ramesh, Ashwanth, Ramírez de Arellano, Manuel Vicente Mejía, Renton, Duncan, Rickman, Stephen, Robertson, Alastair, Roche Albero, Adrian, Rodrigo Verguizas, José Alberto, Rodríguez Couso, Myriam, Rooney, Joanna, Sáez-López, Pilar, Saldaña-Díaz, Andres, Santulli, Adriano, Sanz Pérez, Marta Isabel, Sarraf, Khaled M.; Scarsbrook, Christine, Scott, Chloe E. H.; Scott, Jennifer, Shah, Sachi, Sharaf, Sharief, Sharma, Sidharth, Shirley, Denise, Siano, Antonio, Simpson, James, Singh, Abhinav, Singh, Amit, Sinnett, Tim, Sisodia, Gurudatt, Smith, Philomena, Sophena Bert, Eugenia, Steel, Michael, Stewart, Avril, Stewart, Claire, Sugand, Kapil, Sullivan, Niall, Sweeting, Lauren, Symes, Michael, Tan, Dylan Jun Hao, Tancredi, Francesco, Tatani, Irini, Thomas, Philip, Thomson, Fraser, Toner, Niamh S.; Tong, Anna, Toro, Antonio, Tosounidis, Theodoros, Tottas, Stylianos, Trinidad Leo, Andrea, Tucker, Damien, Vemulapalli, Krishna, Ventura Garces, Diego, Vernon, Olivia Katherine, Viveros Garcia, Juan Carlos, Ward, Alex, Ward, Kirsty, Watson, Kate, Weerasuriya, Thisara, Wickramanayake, Udara, Wilkinson, Hannah, Windley, Joseph, Wood, Janet, Wynell-Mayow, William, Zatti, Giovanni, Zeiton, Moez, Zurrón Lobato, Miriam.
The Surgeon ; 2022.
Article in English | ScienceDirect | ID: covidwho-1763986

ABSTRACT

Aims This international study aimed to assess: 1) the prevalence of preoperative and postoperative COVID-19 among patients with hip fracture, 2) the effect on 30-day mortality, and 3) clinical factors associated with the infection and with mortality in COVID-19-positive patients. Methods A multicentre collaboration among 112 centres in 14 countries collected data on all patients presenting with a hip fracture between 1st March-31st May 2020. Demographics, residence, place of injury, presentation blood tests, Nottingham Hip Fracture Score, time to surgery, management, ASA grade, length of stay, COVID-19 and 30-day mortality status were recorded. Results A total of 7090 patients were included, with a mean age of 82.2 (range 50-104) years and 4959 (70%) being female. Of 651 (9.2%) patients diagnosed with COVID-19, 225 (34.6%) were positive at presentation and 426 (65.4%) became positive postoperatively. Positive COVID-19 status was independently associated with male sex (odds ratio (OR) 1.38, p=0.001), residential care (OR 2.15, p<0.001), inpatient fall (OR 2.23, p=0.003), cancer (OR 0.63, p=0.009), ASA grade 4-5 (OR 1.59, p=0.008;OR 8.28, p<0.001), and longer admission (OR 1.06 for each increasing day, p<0.001). Patients with COVID-19 at any time had a significantly lower chance of 30-day survival versus those without COVID-19 (72.7% versus 92.6%, p<0.001). COVID-19 was independently associated with an increased 30-day mortality risk (hazard ratio (HR) 2.83, p<0.001). Increasing age (HR 1.03, p=0.028), male sex (HR 2.35, p<0.001), renal disease (HR 1.53, p=0.017), and pulmonary disease (HR 1.45, p=0.039) were independently associated with a higher 30-day mortality risk in patients with COVID-19 when adjusting for confounders. Conclusion The prevalence of COVID-19 in hip fracture patients during the first wave of the pandemic was 9%, and was independently associated with a three-fold increased 30-day mortality risk. Among COVID-19-positive patients, those who were older, male, with renal or pulmonary disease had a significantly higher mortality risk.

9.
Revista Latina de Comunicación Social ; - (80):135-160, 2022.
Article in English | ProQuest Central | ID: covidwho-1753812

ABSTRACT

Introduction The current way of consuming content by users (Martisi, 2020) and disseminating it on social networks implies the elimination of the information monopoly of the media and journalists (López, Vives, and Badell, 2018). Several studies address this phenomenon and the emergence of platforms in Spain and other European countries (Vizoso, López, and Pereira, 2019;López Pan and Rodríguez, 2019;Ufarte et al., 2020;García Vivero and López García, 2020), comparing differentiated models of verifiers in terms of verification formulas, organization, and content (Vázquez Herrero et al., 2019), or evidence their essential role in electoral contexts (Noain-Sánchez, 2019;Magallón-Rosa, 2019) or in public discourse in Latin America (Palau-Sampio, 2018). A study has also been identified (Dafonte-Gómez et al., 2019) on the social networks of the group of Hispanic verifiers of the IFCN, although this dates from before the pandemic and is limited to making a global map of their digital presence, in terms of channels and audience figures. In previous stages of the same R+D+i project, in which this study is carried out, we began the analysis of the total number of verifiers of the #CoronavirusFactCheck Alliance, categorizing them according to a set of identifying, organizational, and methodological features (origin and provenance, digital presence, theme, technique and formats used to verify, theme selection criteria, and results classification, etc.).

10.
Revista Latina de Comunicación Social ; - (80):135-161, 2022.
Article in Spanish | ProQuest Central | ID: covidwho-1753811

ABSTRACT

Introducción: Este trabajo explora el uso de las redes sociales por medios hispanos de la #Corona-virusFactCheck Alliance de la International Fact-Checking Network (IFCN) ante la pandemia de la Covid-19 como herramientas para generar contenidos multimedia o interactivos innovadores con los que llegar a nuevos públicos y aumentar su visibilidad. Metodología: Mediante la observación y el análisis de los canales en red se identifican casos relevantes de adaptación de contenidos y se catalogan prácticas innovadoras. Y, a través de entrevistas en profundidad a sus promotores, se determina si esta producción se plantea como estrategia editorial y se recogen percepciones sobre limitaciones, posibilidades y proyectos futuros de contenidos innovadores en red. Resultados: Al margen de la presencia generalizada en Twitter y Facebook, las mayores innovaciones se dan sobre contenidos audiovisuales y sonoros, que van desde resúmenes y curación de contenidos a lo explicativo. Se realizan a través de redes como YouTube, Instagram e incluso TikTok, Twitch y canales de podcasting, empleando narrativas adaptadas a estos canales. Conclusiones: En el marco de determinada estrategia o de forma táctica, más allá de informar, los verificadores buscan formar y movilizar a las audiencias en la lucha contra la infodemia con formatos atractivos, comprensibles y viralizables desde los propios canales donde fluye la desinformación. Si bien algunos cuentan con recursos limitados, participar en la IFCN abre nuevas oportunidades para la innovación editorial.

12.
J Med Virol ; 2021 Nov 11.
Article in English | MEDLINE | ID: covidwho-1718386

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic has particularly affected countries with weakened health services in Latin America, where proper patient management could be a critical step to address the epidemic. In this study, we aimed to characterize and identify which epidemiological, clinical, and paraclinical risk factors defined COVID-19 infection from the first confirmed cases through the first epidemic wave in Venezuela. A retrospective analysis of consecutive suspected cases of COVID-19 admitted to a sentinel hospital was carried out, including 576 patient cases subsequently confirmed for severe acute respiratory syndrome coronavirus 2 infection. Of these, 162 (28.1%) patients met the definition criteria for severe/critical disease, and 414 (71.2%) were classified as mild/moderate disease. The mean age was 47 (SD 16) years, the majority of which were men (59.5%), and the most frequent comorbidity was arterial hypertension (23.3%). The most common symptoms included fever (88.7%), headache (65.6%), and dry cough (63.9%). Severe/critical disease affected mostly older males with low schooling (p < 0.001). Similarly, higher levels of glycemia, urea, aminotransferases, total bilirubin, lactate dehydrogenase, and erythrocyte sedimentation rate were observed in severe/critical disease patients compared to those with mild/moderate disease. Overall mortality was 7.6% (44/576), with 41.7% (28/68) dying in hospital. We identified risk factors related to COVID-19 infection, which could help healthcare providers take appropriate measures and prevent severe clinical outcomes. Our results suggest that the mortality registered by this disease in Venezuela during the first epidemic wave was underestimated. An increase in fatalities is expected to occur in the coming months unless measures that are more effective are implemented to mitigate the epidemic while the vaccination process is ongoing.

13.
J Clin Med ; 11(4)2022 Feb 21.
Article in English | MEDLINE | ID: covidwho-1706493

ABSTRACT

We evaluated in this randomised, double-blind clinical trial the efficacy of melatonin as a prophylactic treatment for prevention of SARS-CoV-2 infection among healthcare workers at high risk of SARS-CoV-2 exposure. Healthcare workers fulfilling inclusion criteria were recruited in five hospitals in Spain and were randomised 1:1 to receive melatonin 2 mg administered orally for 12 weeks or placebo. The main outcome was the number of SARS-CoV-2 infections. A total of 344 volunteers were screened, and 314 were randomised: 151 to placebo and 163 to melatonin; 308 received the study treatment (148 placebo; 160 melatonin). We detected 13 SARS-CoV-2 infections, 2.6% in the placebo arm and 5.5% in the melatonin arm (p = 0.200). A total of 294 adverse events were detected in 127 participants (139 in placebo; 155 in melatonin). We found a statistically significant difference in the incidence of adverse events related to treatment: 43 in the placebo arm and 67 in the melatonin arm (p = 0.040), and in the number of participants suffering from somnolence related to treatment: 8.8% (n = 14) in the melatonin versus 1.4% (n = 2) in the placebo arm (p = 0.008). No severe adverse events related to treatment were reported. We cannot confirm our hypothesis that administration of melatonin prevents the development of SARS-CoV-2 infection in healthcare workers.

14.
BMC Psychiatry ; 22(1): 99, 2022 02 09.
Article in English | MEDLINE | ID: covidwho-1690941

ABSTRACT

BACKGROUND: Emotional disorders are common, and they have become more prevalent since the COVID-19 pandemic. Due to a high attendance burden at the specialized level, most emotional disorders in Spain are treated in primary care, where they are usually misdiagnosed and treated using psychotropic drugs. This contributes to perpetuate their illness and increase health care costs. Following the IAPT programme and the transdiagnostic approach, the PsicAP project developed a brief group transdiagnostic cognitive-behavioural therapy (tCBT) as a cost-effective alternative. However, it is not suitable for everyone; in some cases, one-on-one sessions may be more effective. The objective of the present study is to compare, in cost-benefit terms, group and individual tCBT with the treatment usually administered in Spanish primary care (TAU). METHODS: A randomized, controlled, multicentre, and single-blinded trial will be performed. Adults with mild to moderate emotional disorders will be recruited and placed in one of three arms: group tCBT, individual tCBT, or TAU. Medical data and outcomes regarding emotional symptoms, disability, quality of life, and emotion regulation biases will be collected at baseline, immediately after treatment, and 6 and 12 months later. The data will be used to calculate incremental cost-effectiveness and cost-utility ratios. DISCUSSION: This trial aims to contribute to clinical practice research. The involvement of psychologists in primary care and the implementation of a stepped-care model for mental disorders are recommended. Group therapy and a transdiagnostic approach may help optimize health system resources and unblock waiting lists so that people can spend less time experiencing mental health problems. TRIAL REGISTRATION: ClinicalTrials.gov: NCT04847310; Protocols.io: bx2npqde. (April 19, 2021).


Subject(s)
COVID-19 , Quality of Life , Adult , Cost-Benefit Analysis , Humans , Multicenter Studies as Topic , Pandemics , Primary Health Care , Randomized Controlled Trials as Topic , SARS-CoV-2 , Treatment Outcome
15.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-322537

ABSTRACT

Since its emergence, in December 2019, COVID-19 has resulted in more than 12 million people infected and has killed more than 570000. Hypoxemia has been identified as one of the main clinical manifestations of this disease, especially in severe cases. We have previously reported that in critically ill COVID-19 patients there is a shift towards an immature myeloid profile in peripheral blood cells, including band neutrophils, immature monocytes, metamyelocytes, monocyte-macrophages, monocytoid precursors, and promyelocytes-myelocytes, which, together with mature monocytes and segmented neutrophils, comprise the vast majority of blood cells in these patients. Such an immature myeloid profile may be the result of a physiological response known as emergency myelopoiesis. In the present study, we performed scRNAseq from leukocytes from five critically ill COVID-19 patients and characterized the expression of hypoxia-inducible factor1α (HIF1α) mRNA and its transcriptionally regulated genes. HIF1α is a master transcription factor involved in the cellular response to hypoxia. We herein report that these cellular subsets express high levels of HIF1α mRNA and several of their transcriptional targets, including those related to inflammation, such as CXCL8, CXCR1, CXCR2, and CXCR4;those potentially involved in virus sensing, such as TLR2 and TLR4;and those related to metabolism, such as SLC2A3, PFKFB3, PGK1, GAPDH and SOD2. The up-regulation and participation of HIF1α in relevant events such as inflammation, immunometabolism, and TLR make it a potential molecular marker for COVID-19 severity and, interestingly, could represent a potential target for molecular therapy.

16.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-320150

ABSTRACT

Background: There are no published cases of tonic-clonic seizures and posterior bilateral blindness during pregnancy and SARS-COV-2 infection. We do not just face new and unknown manifestations, but also how different patients groups are affected by SARS-Cov-2 infection, like pregnant women. COVID-19, preeclampsia, eclampsia and posterior reversible leukoencephalopathy share endothelium damage and similar pathophysiology. Case presentation: We present a case of a 35 years old pregnant woman, who comes to our hospital because of tonic-clonic seizures at home and SARS-COV-2 infection. After Caesarean section, we initiate antihypertensive treatment with labetalol, amlodipine and captopril. Few hour after C-section, she develops blindness with total recuperation after 72 hours, normal brain CT scan and normal CT angiography. She had normal pregnancy control and no other symptoms before tonic-clonic seizures development. Conclusion: SARS-COV-2 infection could promote brain endothelial damage and facilitate neurological complications during pregnancy.

17.
EuropePMC; 2021.
Preprint in English | EuropePMC | ID: ppcovidwho-314841

ABSTRACT

Testing and isolation have been crucial for controlling the COVID-19 pandemic. Venezuela has one of the weakest testing infrastructures in Latin America and the low number of reported cases in the country has been attributed to substantial underreporting. However, the Venezuelan epidemic seems to have lagged behind other countries in the region, with most cases occurring within the capital region and four border states. Here, we describe the spatial epidemiology of COVID-19 in Venezuela and its relation to population mobility, migration patterns, non-pharmaceutical interventions and fuel availability. Using an SEI metapopulation model, we explore how movement patterns could have driven the observed distribution of cases. Low within-country connectivity most likely delayed the epidemic in most states, except for those bordering Colombia and Brazil where high immigration seeded outbreaks. NPIs slowed early epidemic growth and subsequent fuel shortages appeared to be responsible for limiting the spread of COVID-19 across the country.

18.
EuropePMC; 2021.
Preprint in English | EuropePMC | ID: ppcovidwho-314526

ABSTRACT

Background: Additional safe and effective vaccines are needed to control the COVID-19 pandemic.Methods: HERALD is an ongoing phase 2b/3 randomised, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America. SARS-CoV-2 naïve adults were randomised 1:1 to receive two doses of CVnCoV mRNA vaccine candidate or placebo 28 days apart. Primary efficacy analysis included symptomatic COVID-19 more than 14 days after second dose. Solicited adverse events (AEs) were assessed in phase 2b participants and unsolicited AEs in all participants. The study is registered at ClinicalTrials.gov (NCT04652102).Findings: Between 11 December 2020 and 12 April 2021, 39 680 participants were randomised and 39 529 received CVnCoV (19 783) or placebo (19 746). Overall VE was 48·2% (95% CI: 31·0–61·4;83/12 851 vs. 145/12 221 in CVnCoV and placebo recipients, respectively). Overall VE against moderate-to-severe COVID-19 was 70·7% (95% CI: 42·5–86·1;12/12 851 vs. 37/12 211, respectively). In participants aged 18–60 years VE was 52·5% (95% CI: 36·2–64·8;71/11 532 vs. 136/11 031, respectively). Too few cases occurred in participants aged ≥61 years (CVnCoV: 12, placebo: 9) precluding VE evaluation. Wild type SARS-CoV-2 was detected in 7/204 (3%) sequenced cases, with 14 variants being responsible for the other cases. Solicited adverse events, mostly systemic, were more common in CVnCoV recipients;542/2002 CVnCoV recipients and 61/1980 placebo recipients reported grade 3 events. Unsolicited serious AEs were reported for 82/19 746 CVnCoV recipients and 66/19 746 placebo recipients;8 and 2 SAEs, respectively were considered related to vaccination. Fatal SAEs were reported for 8 and 6 CVnCoV and placebo recipients.Interpretation: CVnCoV is efficacious in the prevention of COVID-19 of any severity and has an acceptable safety profile.Trial Registration: Study number: ClinicalTrials.gov Identifier: NCT04652102. Funding: This trial was funded by the German Federal Ministry of Education and Research (grant01KI20703), and CureVac AG.Declaration of Interest: MB declares institutional funding from CureVac during the conduct of this study, from Janssen Vaccines, molecular partners, and Merck outside of the submitted work, and consulting fees from Janssen Vaccines. EJLDB, and MFMR, TO and XSL declare institutional funding from CureVac during the conduct of this study. LE, and LG declare institutional funding from CureVac during the conduct of this study and outside of the submitted work. CFL declares institutional funding from CureVac during the conduct of this study, and outside of the submitted work, and is a member of WHO Covid-19 Vaccine Effectiveness Working Group and WHO Product Development for Vaccines Advisory Committee (PDVAC). CL declares institutional funding from CureVac during the conduct of this study, and is a member of the of German Society of Infection board. ILR declares institutional funding from CureVac during the conduct of this study and from J &J, and OSE Immunotherapeutics outside of the submitted work. PGK declares institutional funding from CureVac during the conduct of this study, and is a member of the scientific advisory board for the HERALD clinical trial. VVRH declares institutional funding from CureVac during the conduct of this study, and speakers fees from Gilead outside of the submitted work. HJ declares consultant fees from CureVac, is the Medical Responsible Person for the HERALD clinical trial, and is co-chair of DSMB for the HERALD clinical trial. AK and PM are employed by CureVac, and hold stock options. OSK declares consultant fees from CureVac during the conduct of this study, and is a member of the DSMB for a CVnCoV phase 1 trial. TV declares consultant fees from CureVac during the conduct of this study, and consultant fees from CureVac, AstraZeneca, Pfizer, Johnson&Johnson, and Moderna outside of the submitted work. LO is employed by CureVac, and holds stock options, and is the holder of a pending patent. The other authors declare no competing interests.Ethical Approval: The trial protocol and amendments have been approved by the appropriate independent ethics committee or institutional review board at each study centre

19.
EuropePMC; 2021.
Preprint in English | EuropePMC | ID: ppcovidwho-312866

ABSTRACT

Background: On 8th December 2020, deployment of the first vaccine against SARS-CoV-2 authorised for UK use, the mRNA-based vaccine BNT162b2, began, followed by the adenoviral vector vaccine ChAdOx1nCoV-19 on 4th January 2021. Initially care home-residents and staff, frontline healthcare workers and adults from age 80 were targeted. In phase 3 trials, BNT162b2 and ChAdOx1nCoV-19 demonstrated 95% and 70% efficacy, respectively, after two doses against symptomatic SARS-CoV-2 infection. However, few data exist regarding the effectiveness of these vaccines in elderly frail people. Evaluation following implementation to determine the effectiveness of one dose in reducing hospitalisations due to SARS-CoV-2 infection in elderly adults is urgent.Methods: A prospective single-centre test-negative design case-control study of adults aged ≥80 years hospitalised with COVID-19 disease or other acute respiratory disease. We conducted logistic regression controlling for time (week), gender, index of multiple deprivations (IMD), and care residency status (CRS), and sensitivity analyses matched for time and gender using a conditional logistic model adjusting for IMD and CRS.Findings: First dose vaccine effectiveness of BNT162b2 was 71.4% (95% confidence interval [CI] 46.5-90.6). ChAdOx1nCoV-19 first dose vaccine effectiveness was 80.4% (95% CI 36.4-94.5). When effectiveness analysis for BNT162b2 was restricted to the period covered by ChAdOx1nCoV-19, the estimate was 79.3% (95% CI 47.0-92.5).Interpretation: A single dose of either BNT162b2 or ChAdOx1nCoV-19 vaccine resulted in substantial reductions in the risk of COVID-19-related hospitalisation in elderly, frail patients with extensive co-morbid disease.Funding: The AvonCAP study is an investigator-led project funded under a collaborative agreement by Pfizer.Conflict of Interest: CH is Principal Investigator of the Avon CAP study which is an investigator-led University of Bristol study funded by Pfizer and has previously received support from the NIHR in an Academic Clinical Fellowship. JO is a Co-Investigator on the Avon CAP Study. AF is a member of the Joint Committee on Vaccination and Immunization (JCVI) and chair of the World Health Organization European Technical Advisory Group of Experts on Immunization (ETAGE) committee. In addition to receiving funding from Pfizer as Chief Investigator of this study, he leads another project investigating transmission of respiratory bacteria in families jointly funded by Pfizer and the Gates Foundation. The other authors have no relevant conflicts of interest to declare.Ethical Approval: The study was approved by the Health Research Authority Research Ethics Committee (East of England, Essex), REC 20/EE/0157, including data collection under Section 251 of the 2006 NHS Act authorised by the Confidentiality Advisory Group.

20.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-311362

ABSTRACT

We investigate the performance of optimised three asset portfolios comprised of stocks, bonds and a cryptocurrency or gold for the period immediately before and during the COVID-19 financial crisis. We compare the performance of these portfolios with a two-asset cash portfolio comprised of stocks and bonds. Cryptocurrencies have the potential to control risk as most portfolios that include cryptocurrencies consistently experienced risk no greater than 50 basis points above the risk experienced by cash portfolios. However, there is no free lunch. While three asset portfolios can control risk, they also have a lower return per unit of risk.

SELECTION OF CITATIONS
SEARCH DETAIL